In the COU-AA trial of prednisone alone or in combination with abiraterone, there was a small increase in abnormal liver function tests, with the number of patients with increased AST and ALT doubling from, respectively, 5% and 4.8% of patients with prednisone alone to 13.3% and 12% in patients with prednisone and abiraterone, albeit this involved a small number of patients and the effect was not quite significant [ 140 , 141 ].
← all excerpts
Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy.
1
—
—